Ionis Pharmaceuticals
Search results
Jun 28, 2024 · BioMarin is a global biotechnology company that has developed medicines to treat conditions such as achondroplasia, severe hemophilia A, and several rare inherited and lysosomal storage diseases. Learn more.
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs).
BioMarin is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health.
Find the latest BioMarin Pharmaceutical Inc. (BMRN) stock quote, history, news and other vital information to help you with your stock trading and investing.
Products and Pipeline. For more than two decades, we have leveraged expertise in genetics and genomics to create new medicines for people with serious medical conditions.
Nov 1, 2023 · In the third quarter, patient growth remained strong worldwide. Based on these trends, and the expectation that approximately 2,600 children will be receiving VOXZOGO treatment by year-end, today the company updated full-year 2023 VOXZOGO guidance to between $435 million and $455 million.
Aug 24, 2022 · Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity. Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA Determination of ODD. Conference Call and Webcast to be Held Wed., Aug. 24th at 8:00 pm Eastern.
Get the latest Biomarin Pharmaceutical Inc (BMRN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Feb 22, 2024 · On February 22, 2024, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its 8-K filing, detailing a record-setting financial performance for the fourth quarter and full year of 2023. The...
Jun 29, 2023 · The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for severe hemophilia A, the company said, giving patients with the inherited bleeding...
